This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
- Immunotherapy via PD-L1-presenting biomaterials leads to long-term islet graft survival
- Diels-Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody
- Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
- A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Protein for Pretargeted Radioimmunotherapy of Hematologic Malignancies
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Pretargeted Radioimmunotherapy with a Single-Chain Antibody/Streptavidin Construct and Radiolabeled DOTA-Biotin: Strategies for Reduction of the Renal Dose
- Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein
- Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate
- Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
- Pretargeted Radioimmunotherapy of Mesothelin-Expressing Cancer Using a Tetravalent Single-Chain Fv-Streptavidin Fusion Protein
- Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies
- Current Status of Therapy of Solid Tumors
- Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
- Single-Chain Fv-Streptavidin Substantially Improved Therapeutic Index in Multistep Targeting Directed at Disialoganglioside GD2
- Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin
- Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy
- Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy
- Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen x Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial
- Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
- Radioimmunotherapy of A431 Xenografted Mice with Pretargeted B3 Antibody-Streptavidin and 90Y-labeled 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid (DOTA)-Biotin
- Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213
- Targeted Therapy of Cancer with Radiolabeled Antibodies
- Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
- Cloning and Characterization of Scavidin, a Fusion Protein for the Targeted Delivery of Biotinylated Molecules
- A 3-Step Pretargeting Strategy to Image Infection
- In Vivo Biotin Supplementation at a Pharmacologic Dose Decreases Proliferation Rates of Human Peripheral Blood Mononuclear Cells and Cytokine Release
- The Clearance and Metabolism of Biotin Administered Intravenously to Pigs in Tracer and Physiologic Amounts Is Much More Rapid than Previously Appreciated
- A Tetravalent Single-chain Antibody-Streptavidin Fusion Protein for Pretargeted Lymphoma Therapy
- How Far Have We Come with Solid (Nonhematologic) Tumor Radioimmunotherapy?